Table of contents  by unknown
525 Can the use of methylprednisolone, vitamin C, or -trinositol prevent cold-
induced fluid extravasation during cardiopulmonary bypass in piglets?
M. Farstad, MD, J. K. Heltne, MD, PhD, S. E. Rynning, MD, PhD, H. Onarheim, MD, PhD,
A. Mongstad, RP, F. Eliassen, RP, and P. Husby, MD, PhD, Bergen, Norway
Three different treatment protocols (methylprednisolone, vitamin C, and -trinositol) known to
reduce microvascular leakage during either cardiovascular bypass or thermal injuries were
tested, but none reduced the microvascular leakage present during hypothermic cardiovascular
bypass.
535 Adenoviral-mediated transfer of vascular endothelial growth factor 121
cDNA enhances myocardial perfusion and exercise performance in the
nonischemic state
Paul Schalch, MD, G. Farah Rahman, MD, Gerald Patejunas, PhD,
Robert A. Goldschmidt, MD, JoAnn Carbray, BS, Mauricio A. Retuerto, BS, David Kim, BS,
Karyn Esser, PhD, Ronald G. Crystal, MD, and Todd K. Rosengart, MD, Evanston and
Chicago, Ill, and New York, NY
It is unknown whether the administration of angiogenic growth factors will increase blood flow
to nonischemic tissues. An adenovirus encoding VEGF121 (AdVEGF), an adenovirus with an
empty expression cassette (AdNull), or saline solution was administered intramyocardially to
normal rabbits and rats to test this hypothesis. The myocardial perfusion index 4 weeks after
AdVEGF administration was greater than that for rabbits injected with AdNull or saline
solution (3.2  0.5 vs 2.7  0.7 and 2.4  0.4, respectively; P  .03). AdVEGF-treated rats
demonstrated prolonged exercise tolerance compared with rats injected with AdNull or saline
solution (exhaustion time: 26  5 minutes vs 19  2 minutes and 20  3 minutes,
respectively; P  .006). Adenovirus-mediated transfer of VEGF121 induces an enhancement in
regional perfusion and vascularization in nonischemic myocardium that corresponds to changes
in exercise tolerance.
541 Tumor necrosis factor- from resident lung cells is a key initiating factor in
pulmonary ischemia-reperfusion injury
Thomas S. Maxey, MD, Richard I. Enelow, MD, Benjamin Gaston, MD, Irving L. Kron, MD,
Victor E. Laubach, PhD, and Allan Doctor, MD, Charlottesville, Va
With the use of an isolated, buffer-perfused murine lung system, we demonstrated that lungs
from TNF-–deficient mice are protected from ischemia-reperfusion injury. This indicates that
TNF- from resident lung cells is a key initiating factor in pulmonary ischemia-reperfusion
injury.
548 Preoperative detection and management of immune heparin-induced
thrombocytopenia in patients undergoing heart surgery with iloprost
George M. Palatianos, MD, Christophoros N. Foroulis, MD, Maria I. Vassili, MD,
Phaedra Matsouka, MD, George M. Astras, MD, George H. Kantidakis, MD,
Eugenia Iliopoulou, BSc, and Efthimia N. Melissari, MD, Athens, Greece
Heparin-induced thrombocytopenia type II was diagnosed by heparin-induced platelet
aggregation and ELISA tests before admission in 10 of 32 patients (31.25%) scheduled to
undergo cardiac surgery. The patients had platelet counts less than 150,000/mm3 or previous
prolonged (5 days) exposure to heparin or both, and underwent operation safely with
temporary, iloprost-induced platelet inhibition during heparin anticoagulation.
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